FMS logo

FRESENIUS MEDICAL CARE-ADR

FMSNYSE
πŸ† #793 by market capEarnings Nov 3US Equity
$22.27β–Ό $0.65 (βˆ’2.94%)
πŸŒ™ After hours$22.27β–² 0.00%Regular close Β· extended-hours price shown
πŸ””
Track FMS
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 2.9%
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$11.96B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
+1.5%
Slowing
πŸ“ŠGross Margin
26.4%
Moderate
πŸ’΅FCF Margin
9.2%
Moderate
βš–οΈP/S Ratio
0.5x
Cheap
Otter Score
56
Weak
No chart data available for FMS.

Trading Snapshot

Day Range
$22.06 – $22.56
52-Week Range
$20.02 – $27.64
Volume
$2.43B
Avg Volume
$2.26B
Shares Outstanding
537.1M
Next Earnings
Nov 15, 2026

Fundamentals Snapshot

Annual Revenue
$19.63B
Last Q Revenue
$4.86B
P/E Ratio
11.8
P/S Ratio
0.5x
EPS (TTM)
$1.75
Dividend Yield
3.80%
Dilution (1yr)
βˆ’51.3%

Why Investors Own FMS

  • βœ“High-growth profile β€” revenue up -7.6% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 58% gross margin and 20% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

FMS logo

FRESENIUS MEDICAL CARE-ADR

FMS
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$19.6Bβ–² +1.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
25.6%β–² +4.2% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$1.8Bβ–² +24.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$1.7Bβ–² +0.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
571.8Mβ–Ό βˆ’51.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$9.2Bβ–² +$628M YoY
StockOtter Β· stockotter.space

About FRESENIUS MEDICAL CARE-ADR

Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a prominent developer, manufacturer, and distributor of a broad range of dialysis products. This portfolio encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, the company produces non-dialysis medical devices, including acute cardiopulmonary and apheresis products. Its pharmaceutical division focuses on developing, acquiring, and in-licensing specialized renal medications, distributing these essential drugs and supplies to both individual patients' homes and dialysis centers. The company also extends its medical offerings to include a variety of specialized services such as vascular, cardiovascular, and endovascular care, operating ambulatory surgery centers for vascular procedures, and providing physician services in nephrology and cardiology. Products are sold directly to dialysis clinics, hospitals, and specialized treatment centers, complemented by sales through local teams, independent distributors, dealers, and agents. By February 23, 2022, Fresenius Medical Care managed an impressive network of 4,171 outpatient dialysis clinics across roughly 150 countries. Established in 1996, the company maintains its headquarters in Bad Homburg, Germany.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Weak
56/100

Analyst Ratings

β“˜
Consensus
Hold
29 analysts
Strong Buy3
Buy3
Hold11
Sell10
Strong Sell2
Ratings as of Sep 2026

Latest News & Updates

πŸš€
Zacks Investment ResearchΒ·10h ago

Fresenius Medical Care Reshapes China Portfolio for Long-Term Growth

FMS refines its China strategy around advanced dialysis and critical-care technologies, with 110M euros in one-time costs.

Defense WorldΒ·1d ago

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Stock Has Consensus Price Target of $23.57 According to Brokerages

Fresenius Medical Care AG and Co. KGaA (NYSE: FMS - Get Free Report) has received an average recommendation of "Reduce" from the eleven ratings firms that are currently covering the firm, Marketbeat Ratings reports. Five

PRNewsWireΒ·4d ago

Fresenius Medical Care Refines China Commercial Strategy with a Focus on Long-Term Growth and Market Leadership

Refinements support the Company's China go-to-market and commercial strategy in an important and growing market Strategy focuses on localized portfolio and innovation in China Portfolio decisions expected to result in re

Defense WorldΒ·12d ago

Tidal Investments LLC Buys 48,885 Shares of Fresenius Medical Care AG & Co. KGaA $FMS

Tidal Investments LLC grew its stake in shares of Fresenius Medical Care AG and Co. KGaA (NYSE: FMS) by 96.0% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exch

Zacks Investment ResearchΒ·26d ago

Can Fresenius Medical's 5008X Rollout Drive the Next Growth Phase?

Fresenius Medical is scaling its 5008X rollout across U.S. clinics, creating growth potential despite volume, reimbursement and rollout-cost pressures.

Zacks Investment ResearchΒ·26d ago

Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now

Fresenius Medical's improving profitability, 5008X rollout and value-based care gains offer support despite volume and reimbursement risks.